MEDICENNA THERAPEUTICS CORP (MDNA.CA) Fundamental Analysis & Valuation

TSX:MDNA • CA58490H1073

0.87 CAD
-0.01 (-1.14%)
Last: Mar 3, 2026, 07:00 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership News

This MDNA.CA fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

1

We assign a fundamental rating of 1 out of 10 to MDNA. MDNA was compared to 24 industry peers in the Biotechnology industry. MDNA scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. MDNA does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

1

1. MDNA.CA Profitability Analysis

1.1 Basic Checks

  • MDNA had negative earnings in the past year.
  • MDNA had a negative operating cash flow in the past year.
  • MDNA had negative earnings in each of the past 5 years.
  • In the past 5 years MDNA always reported negative operating cash flow.
MDNA.CA Yearly Net Income VS EBIT VS OCF VS FCFMDNA.CA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -5M -10M -15M -20M -25M

1.2 Ratios

  • The Return On Assets of MDNA (-99.41%) is comparable to the rest of the industry.
  • Looking at the Return On Equity, with a value of -209.08%, MDNA is in the better half of the industry, outperforming 66.67% of the companies in the same industry.
Industry RankSector Rank
ROA -99.41%
ROE -209.08%
ROIC N/A
ROA(3y)-67.42%
ROA(5y)-67.89%
ROE(3y)-195.49%
ROE(5y)-148.03%
ROIC(3y)N/A
ROIC(5y)N/A
MDNA.CA Yearly ROA, ROE, ROICMDNA.CA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -100 -200 -300 -400

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for MDNA so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
MDNA.CA Yearly Profit, Operating, Gross MarginsMDNA.CA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

4

2. MDNA.CA Health Analysis

2.1 Basic Checks

  • MDNA has more shares outstanding than it did 1 year ago.
  • Compared to 5 years ago, MDNA has more shares outstanding
  • MDNA has a worse debt/assets ratio than last year.
MDNA.CA Yearly Shares OutstandingMDNA.CA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M
MDNA.CA Yearly Total Debt VS Total AssetsMDNA.CA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M 40M

2.2 Solvency

  • Based on the Altman-Z score of -12.73, we must say that MDNA is in the distress zone and has some risk of bankruptcy.
  • Looking at the Altman-Z score, with a value of -12.73, MDNA is in line with its industry, outperforming 54.17% of the companies in the same industry.
  • MDNA has a Debt/Equity ratio of 0.01. This is a healthy value indicating a solid balance between debt and equity.
  • The Debt to Equity ratio of MDNA (0.01) is better than 83.33% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Altman-Z -12.73
ROIC/WACCN/A
WACCN/A
MDNA.CA Yearly LT Debt VS Equity VS FCFMDNA.CA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20M -20M

2.3 Liquidity

  • A Current Ratio of 2.68 indicates that MDNA has no problem at all paying its short term obligations.
  • With a decent Current ratio value of 2.68, MDNA is doing good in the industry, outperforming 70.83% of the companies in the same industry.
  • MDNA has a Quick Ratio of 2.68. This indicates that MDNA is financially healthy and has no problem in meeting its short term obligations.
  • With a decent Quick ratio value of 2.68, MDNA is doing good in the industry, outperforming 70.83% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 2.68
Quick Ratio 2.68
MDNA.CA Yearly Current Assets VS Current LiabilitesMDNA.CA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M 40M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

0

3. MDNA.CA Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 59.46% over the past year.
EPS 1Y (TTM)59.46%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%28.57%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • Based on estimates for the next years, MDNA will show a very negative growth in Earnings Per Share. The EPS will decrease by -65.36% on average per year.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-53%
EPS Next 2Y-72.97%
EPS Next 3Y-65.36%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
MDNA.CA Yearly Revenue VS EstimatesMDNA.CA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2027 2028 2029 2030 2031 20M 40M 60M 80M
MDNA.CA Yearly EPS VS EstimatesMDNA.CA Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 -0.2 -0.4 -0.6

More info and screens

Find the best growth stocksShow best growing peers

0

4. MDNA.CA Valuation Analysis

4.1 Price/Earnings Ratio

  • MDNA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for MDNA. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
MDNA.CA Price Earnings VS Forward Price EarningsMDNA.CA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
MDNA.CA Per share dataMDNA.CA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.1 -0.2 -0.3 -0.4

4.3 Compensation for Growth

  • MDNA's earnings are expected to decrease with -65.36% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-72.97%
EPS Next 3Y-65.36%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. MDNA.CA Dividend Analysis

5.1 Amount

  • No dividends for MDNA!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

MDNA.CA Fundamentals: All Metrics, Ratios and Statistics

MEDICENNA THERAPEUTICS CORP

TSX:MDNA (3/3/2026, 7:00:00 PM)

0.87

-0.01 (-1.14%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-12
Earnings (Next)06-23
Inst Owners6.32%
Inst Owner ChangeN/A
Ins Owners14.4%
Ins Owner ChangeN/A
Market Cap72.57M
Revenue(TTM)N/A
Net Income(TTM)-12.99M
Analysts82
Price Target3.09 (255.17%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)12.71%
Min EPS beat(2)7.12%
Max EPS beat(2)18.3%
EPS beat(4)3
Avg EPS beat(4)35.11%
Min EPS beat(4)-17.65%
Max EPS beat(4)132.68%
EPS beat(8)5
Avg EPS beat(8)-10.3%
EPS beat(12)9
Avg EPS beat(12)1.21%
EPS beat(16)13
Avg EPS beat(16)12.08%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-13.57%
EPS NQ rev (1m)17.95%
EPS NQ rev (3m)17.95%
EPS NY rev (1m)0%
EPS NY rev (3m)11.76%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)-100%
Revenue NY rev (1m)N/A
Revenue NY rev (3m)-100%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 11.68
P/tB 11.77
EV/EBITDA N/A
EPS(TTM)-0.15
EYN/A
EPS(NY)-0.45
Fwd EYN/A
FCF(TTM)-0.22
FCFYN/A
OCF(TTM)-0.22
OCFYN/A
SpS0
BVpS0.07
TBVpS0.07
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -99.41%
ROE -209.08%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-67.42%
ROA(5y)-67.89%
ROE(3y)-195.49%
ROE(5y)-148.03%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.68
Quick Ratio 2.68
Altman-Z -12.73
F-Score2
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)59.46%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%28.57%
EPS Next Y-53%
EPS Next 2Y-72.97%
EPS Next 3Y-65.36%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-19.4%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-34.58%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-34.58%
OCF growth 3YN/A
OCF growth 5YN/A

MEDICENNA THERAPEUTICS CORP / MDNA.CA FAQ

Can you provide the ChartMill fundamental rating for MEDICENNA THERAPEUTICS CORP?

ChartMill assigns a fundamental rating of 1 / 10 to MDNA.CA.


Can you provide the valuation status for MEDICENNA THERAPEUTICS CORP?

ChartMill assigns a valuation rating of 0 / 10 to MEDICENNA THERAPEUTICS CORP (MDNA.CA). This can be considered as Overvalued.


What is the profitability of MDNA stock?

MEDICENNA THERAPEUTICS CORP (MDNA.CA) has a profitability rating of 1 / 10.